These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19118050)
1. BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Litzenburger BC; Kim HJ; Kuiatse I; Carboni JM; Attar RM; Gottardis MM; Fairchild CR; Lee AV Clin Cancer Res; 2009 Jan; 15(1):226-37. PubMed ID: 19118050 [TBL] [Abstract][Full Text] [Related]
2. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Kim HJ; Litzenburger BC; Cui X; Delgado DA; Grabiner BC; Lin X; Lewis MT; Gottardis MM; Wong TW; Attar RM; Carboni JM; Lee AV Mol Cell Biol; 2007 Apr; 27(8):3165-75. PubMed ID: 17296734 [TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563 [TBL] [Abstract][Full Text] [Related]
4. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823 [TBL] [Abstract][Full Text] [Related]
5. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496 [TBL] [Abstract][Full Text] [Related]
6. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250 [TBL] [Abstract][Full Text] [Related]
8. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999 [TBL] [Abstract][Full Text] [Related]
9. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Yanochko GM; Eckhart W Breast Cancer Res; 2006; 8(2):R18. PubMed ID: 16584539 [TBL] [Abstract][Full Text] [Related]
10. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892 [TBL] [Abstract][Full Text] [Related]
11. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487 [TBL] [Abstract][Full Text] [Related]
12. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208 [TBL] [Abstract][Full Text] [Related]
13. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Lisztwan J; Pornon A; Chen B; Chen S; Evans DB Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593 [TBL] [Abstract][Full Text] [Related]
15. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. Franks SE; Jones RA; Briah R; Murray P; Moorehead RA BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578 [TBL] [Abstract][Full Text] [Related]
16. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546 [TBL] [Abstract][Full Text] [Related]
17. Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini. Klos KS; Warmka JK; Drachenberg DM; Chang L; Luxton GW; Leung CT; Schwertfeger KL; Wattenberg EV PLoS One; 2014; 9(3):e90722. PubMed ID: 24599099 [TBL] [Abstract][Full Text] [Related]
18. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410 [TBL] [Abstract][Full Text] [Related]
19. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures. Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860 [TBL] [Abstract][Full Text] [Related]
20. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Novosyadlyy R; Lann DE; Vijayakumar A; Rowzee A; Lazzarino DA; Fierz Y; Carboni JM; Gottardis MM; Pennisi PA; Molinolo AA; Kurshan N; Mejia W; Santopietro S; Yakar S; Wood TL; LeRoith D Cancer Res; 2010 Jan; 70(2):741-51. PubMed ID: 20068149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]